Virtual Medicine – To be or not to be the standard of care for CKD/ESRD patients

DOWNLOAD A PDF OF THE PRESENTATION

Cocktails: 6:30 pm – 7:00 pm EST

Debate: 7:00 pm – 8:15 pm EST

This event is only available to active CSN members and partners


Learning Objectives

Upon completion of this program, participants will be able to:

  • Understand the meaning and spectrum of “virtual care”
  • Explore the current and proximate future context for virtual care
  • Debate the pros and cons of widespread ongoing use of virtual care beyond the Pandemic

This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada, and approved by The Canadian Society of Nephrology. You may claim a maximum of 1.25 hours (credits are automatically calculated).


DEBATERS


Dr. Claudio Rigatto (Pro Side)
Winnipeg, MB

Dr. Claudio Rigatto is a Kidney specialist and an Associate Professor of Medicine at the University of Manitoba, as well a researcher and Academic Director at the Chronic Disease Innovation Centre. Dr. Rigatto is a recognized expert in biomarkers, point-of-care lab testing, telemonitoring and risk prediction in kidney disease. His current work is focused on using digital health technology to help patients safely and confidently treat and monitor their kidney disease at home. As a researcher, he has published over 180 peer reviewed articles, has presented at numerous national and international meetings, and has held leadership positions in various academic and health care system a more patient centered system.



Dr. Andrew House (Con Side)

Dr. Andrew House is a Professor in the Faculty of Medicine at the Schulich School of Medicine & Dentistry, Western University, London, Ontario, and is currently the Chair of the Western University Division of Nephrology, and the Chief of Nephrology at London Health Sciences Centre. He did his training in Physiology & Pharmacology at Western before his MD and specialist training at the University of Ottawa, and Masters in Epidemiology & Biostatistics at Western. As a trained clinical epidemiologist and nephrologist, Dr. House focuses on the design and analysis of clinical trials in hemodialysis and transplantation and has a long-standing interest in continuous renal replacement therapies and the metabolism of homocysteine. In 2007 he completed a six month sabbatical in Vicenza, Italy, where he developed his interests in Critical Care Nephrology and Cardiorenal Syndromes. He is an invited speaker at national and international conferences, and an award-winning teacher of Renal Physiology at Western University.



Moderator

Prof. Deborah Zimmerman, MD, MSc
University of Ottawa, Ottawa, ON